<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95855">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01989156</url>
  </required_header>
  <id_info>
    <org_study_id>ZRHM-REXA-08-US</org_study_id>
    <secondary_id>ZRHM-REXA-08-US</secondary_id>
    <nct_id>NCT01989156</nct_id>
  </id_info>
  <brief_title>Reduced Exposure Study Using the Tobacco Heating System 2.2 (THS 2.2) Menthol for 91 Days in Confinement and Ambulatory</brief_title>
  <official_title>A Randomized, Controlled, Multi-center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Smokers Switching to THS 2.2 Menthol or Smoking Abstinence Compared to Smoking Menthol Conventional Cigarettes, for 91 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Morris Products S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philip Morris Products S.A.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of the study is to evaluate if the ad libitum use of the THS 2.2 Menthol for 5
      days in confinement, and after 86 days in an ambulatory setting, by apparently adult healthy
      smokers results in a reduction in the levels of biomarkers of exposure for selected harmful
      and potentially harmful constituents (HPHCs) compared to smokers continuing smoking their
      own preferred brand of menthol conventional cigarette (mCC) and smoking abstinence (SA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>The evaluation of the total levels of monohydroxybutenyl mercapturic acid (MHBMA); 3-hydroxypropylmercapturic acid (3-HPMA); S-phenylmercapturic acid (S-PMA); total4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (total NNAL) in 24 hours urine.</measure>
    <time_frame>MHBMA, 3-HPMA, S-PMA at 5 days; total NNAL at 91 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To demonstrate the reduction of exposure to respectively 1,3-butadiene; acrolein; benzene HPHCs) after 5 days and to 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) after 91 days of switching from  mCC to THS 2.2 Menthol as compared to mCC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The evaluation of the total levels of carboxyhemoglobin (COHb) in blood.</measure>
    <time_frame>91 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>To demonstrate the reduction of exposure to  carbon monoxide (CO) after 5 days of switching from  mCC to THS 2.2 Menthol as compared to mCC.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>THS 2.2 Menthol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad libitum use of THS 2.2 Menthol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SA</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Abstinence from smoking</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mCC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ad libitum use of mCC</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>THS 2.2 Menthol</intervention_name>
    <description>THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting</description>
    <arm_group_label>THS 2.2 Menthol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SA</intervention_name>
    <description>SA for 5 days in confinement prolonged by 86 days in an ambulatory setting</description>
    <arm_group_label>SA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mCC</intervention_name>
    <description>Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting</description>
    <arm_group_label>mCC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Smoking, apparently healthy subject as judged by the Investigator.

          -  Subject smokes at least 10 commercially available mCCs per day (no brand
             restrictions) for the last 4 weeks, based on self-reporting.

          -  Subject has smoked for at least the last 3 consecutive years.

          -  Subject does not plan to quit smoking within the next 6 months.

        Exclusion Criteria:

          -  As per Investigator judgment, the subject cannot participate in the study for any
             reason (e.g., medical, psychiatric, and/or social reason).

          -  The subject has received medication within 14 days or within 5 half-lives of the
             medication (whichever is longer), which has an impact on CYP1A2 or CYP2A6 activity.

          -  For women: Subject is pregnant or is breast feeding.

          -  For women: Subject does not agree to use an acceptable method of effective
             contraception.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Lewis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Dallas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank Farmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Daytona Beach</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christelle Haziza, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Philip Morris Products S.A.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>William Lewis, MD</last_name>
    <phone>+1-214-920-9053</phone>
    <email>William.Lewis@Covance.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frank Farmer, MD</last_name>
    <phone>+1-386-366-6400</phone>
    <email>Farmer@Covance.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Covance Daytona Beach, 1900 Mason Ave., Suite 140</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Farmer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frank Farmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Covance Dallas, 1341 W. Mockingbird Ln., Ste 400E</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Lewis, MD</last_name>
    </contact>
    <investigator>
      <last_name>William Lewis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>November 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking</keyword>
  <keyword>Candidate modified risk tobacco product</keyword>
  <keyword>Menthol conventional cigarettes</keyword>
  <keyword>Reduced exposure</keyword>
  <keyword>HPHCs</keyword>
  <keyword>Ambulatory</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Smoking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
